RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Canntab Therapeutics Stock

Canntab Therapeutics Equity 2024

Canntab Therapeutics Equity

-311,219.99 CAD

Ticker

PILL.CN

ISIN

CA1377991023

WKN

A2JKBY

In 2024, Canntab Therapeutics's equity was -311,219.99 CAD, a -113.72% increase from the 2.27 M CAD equity in the previous year.

Canntab Therapeutics Aktienanalyse

What does Canntab Therapeutics do?

Canntab Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Canntab Therapeutics's Equity

Canntab Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Canntab Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Canntab Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Canntab Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Canntab Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Canntab Therapeutics stock

What is the equity of Canntab Therapeutics this year?

Canntab Therapeutics has equity of -311,219.99 CAD this year.

What was the equity of Canntab Therapeutics compared to the previous year?

The equity of Canntab Therapeutics has increased/decreased by -113.72% decreased compared to the previous year.

What impact does a high equity have on investors of Canntab Therapeutics?

A high equity is advantageous for investors of Canntab Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Canntab Therapeutics?

A low equity can be a risk for investors of Canntab Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Canntab Therapeutics affect the company?

An increase in equity of Canntab Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Canntab Therapeutics affect the company?

A reduction in equity of Canntab Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Canntab Therapeutics?

Some factors that can affect the equity of Canntab Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Canntab Therapeutics so important for investors?

The equity of Canntab Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Canntab Therapeutics take to change the equity?

To change equity, Canntab Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Canntab Therapeutics pay?

Over the past 12 months, Canntab Therapeutics paid a dividend of 2.9 CAD . This corresponds to a dividend yield of about 58,000 %. For the coming 12 months, Canntab Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Canntab Therapeutics?

The current dividend yield of Canntab Therapeutics is 58,000 %.

When does Canntab Therapeutics pay dividends?

Canntab Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Canntab Therapeutics?

Canntab Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Canntab Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Canntab Therapeutics located?

Canntab Therapeutics is assigned to the '-' sector.

Wann musste ich die Aktien von Canntab Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Canntab Therapeutics from 4/30/2016 amounting to 0.015 CAD, you needed to have the stock in your portfolio before the ex-date on 3/8/2016.

When did Canntab Therapeutics pay the last dividend?

The last dividend was paid out on 4/30/2016.

What was the dividend of Canntab Therapeutics in the year 2023?

In the year 2023, Canntab Therapeutics distributed 0 CAD as dividends.

In which currency does Canntab Therapeutics pay out the dividend?

The dividends of Canntab Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Canntab Therapeutics

Our stock analysis for Canntab Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Canntab Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.